Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Warfarin dosing test

This article was originally published in The Gray Sheet

Executive Summary

Kimball Genetics joins the small number of labs performing pharmacogenetic tests for warfarin therapy with the launch of its Warfarin DoseAdvise June 5. The test, performed at Kimball's CLIA-certified lab in Denver, analyzes genes in blood or cheek cell samples to inform dosing of the common blood thinner. According to Kimball CEO Annette Taylor, FDA plans to revise warfarin product labeling to advocate genetic testing. Other labs offering warfarin dosing tests include Clinical Data (PGxPredict). Third Wave, which sells reagents for warfarin tests, is developing the Invader warfarin in vitro diagnostic (1"The Gray Sheet" March 6, 2006, p. 12)...

You may also be interested in...

Third Wave, Now An IVD Company, Is Banking On Personalized Medicine

Third Wave Technologies is banking on its emerging portfolio of in vitro diagnostic products designed to tailor drug therapy to recover from substantial revenue losses in its research products business

Belgium Aims To Drive Biologic Competition Through Tendering

New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.

EU Bodies Agree On Ways To Future-Proof EMA Funding System

EU ministers say that implementing an appropriate fee structure that is more in line with actual costs will promote innovation in the pharmaceutical sector while ensuring “fair access” to safe and effective medicines for patients.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts